## Lei Song

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/458890/publications.pdf

Version: 2024-02-01

		279798	315739
105	1,993	23	38
papers	citations	h-index	g-index
110	110	110	2866
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Deleterious Rare Desmosomal Variants Contribute to Hypertrophic Cardiomyopathy and Are Associated With Distinctive Clinical Features. Canadian Journal of Cardiology, 2022, 38, 41-48.	1.7	6
2	Patterns of Replacement Fibrosis in Hypertrophic Cardiomyopathy. Radiology, 2022, 302, 298-306.	<b>7.</b> 3	25
3	Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy. BMC Medicine, 2022, 20, 21.	5.5	5
4	Effect of Cis-Compound Variants in MYH7 on Hypertrophic Cardiomyopathy With a Mild Phenotype. American Journal of Cardiology, 2022, 167, 104-110.	1.6	3
5	Heart-specific DNA methylation analysis in plasma for the investigation of myocardial damage. Journal of Translational Medicine, 2022, 20, 36.	4.4	7
6	Post-PCI outcomes predicted by pre-intervention simulation of residual quantitative flow ratio using augmented reality. International Journal of Cardiology, 2022, 352, 33-39.	1.7	15
7	Implications of structural right ventricular involvement in patients with hypertrophic cardiomyopathy. European Heart Journal Quality of Care & Dinical Outcomes, 2022, 9, 34-41.	4.0	3
8	Outcomes of quantitative flow ratio-based percutaneous coronary intervention in an all-comers study. EuroIntervention, 2022, 17, 1240-1251.	3.2	10
9	Effects of diabetes mellitus on post-intervention coronary physiological assessment derived by quantitative flow ratio in patients with coronary artery disease underwent percutaneous coronary intervention. Diabetes Research and Clinical Practice, 2022, 186, 109839.	2.8	10
10	Metabolic characterization of hypertrophic cardiomyopathy in human heart., 2022, 1, 445-461.		8
11	18F-FDG PET/CT plays a unique role in the management of Takayasu arteritis patients with atypical manifestations. Clinical Rheumatology, 2021, 40, 625-633.	2.2	5
12	Clinical characteristics and outcomes of chronic heart failure in adult Takayasu arteritis: A cohort study of 163 patients. International Journal of Cardiology, 2021, 325, 103-108.	1.7	4
13	Association of <i>NPC1L1</i> and <i>HMGCR</i> Gene Polymorphisms with Major Adverse Cardiac and Cerebrovascular Events in Patients with Three-Vessel Disease. Human Gene Therapy, 2021, 32, 581-588.	2.7	5
14	Deep learning algorithm to improve hypertrophic cardiomyopathy mutation prediction using cardiac cine images. European Radiology, 2021, 31, 3931-3940.	4.5	24
15	Body mass index and mortality in patients with severe coronary artery diseases: A cohort study from China. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 448-454.	2.6	7
16	Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3Âyears study from China. Cardiovascular Diabetology, 2021, 20, 16.	6.8	7
17	Association of Acute Procedural Results With Long-Term Outcomes After CTO PCI. JACC: Cardiovascular Interventions, 2021, 14, 278-288.	2.9	22
18	Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12â€month results from a proofâ€ofâ€principle trial. Catheterization and Cardiovascular Interventions, 2021, 97, 976-981.	1.7	8

#	Article	IF	CITATIONS
19	Angiographic characteristics and longâ€term outcomes of singleâ€vessel chronic total occlusion percutaneous coronary intervention in patients with and without previous myocardial infarction. Catheterization and Cardiovascular Interventions, 2021, 97, 1089-1096.	1.7	0
20	Variant Spectrum of Formin Homology 2 Domainâ€Containing 3 Gene in Chinese Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2021, 10, e018236.	3.7	10
21	Association of symptom status, myocardial viability, and clinical/anatomic risk on longâ€term outcomes after chronic total occlusion percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 97, 996-1008.	1.7	3
22	Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With CoronaryÂArtery Disease. JACC: Cardiovascular Interventions, 2021, 14, 1450-1462.	2.9	10
23	Integrated transcriptomics and epigenomics reveal chamber-specific and species-specific characteristics of human and mouse hearts. PLoS Biology, 2021, 19, e3001229.	5.6	5
24	Clinical predictors of the presence of obstructive sleep apnea in patients with hypertrophic cardiomyopathy. Scientific Reports, 2021, 11, 13528.	3.3	2
25	Implications of Periprocedural Myocardial Biomarker Elevations and Commonly Used MI Definitions After Left Main PCI. JACC: Cardiovascular Interventions, 2021, 14, 1623-1634.	2.9	27
26	A Chinese pedigree with glucocorticoid remediable aldosteronism. Hypertension Research, 2021, 44, 1428-1433.	2.7	3
27	Prevalence and Risk Factors for Hypertension in Adolescents Aged 12 to 17 Years: A School-Based Study in China. Hypertension, 2021, 78, 1577-1585.	2.7	10
28	Impact of Periprocedural Myocardial Injury and Infarction Definitions on Long-Term Mortality After Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2021, 14, e010923.	3.9	3
29	Truncating Variants in <i>OBSCN</i> Gene Associated With Disease-Onset and Outcomes of Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003401.	3.6	5
30	N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy. Heart, 2021, 107, 1576-1583.	2.9	19
31	Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. Lancet, The, 2021, 398, 2149-2159.	13.7	175
32	Effect of NPC1L1 and HMGCR Genetic Variants With Premature Triple-Vessel Coronary Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 704501.	2.4	5
33	Effect of Coronary Calcification Severity on Measurements and Diagnostic Performance of CT-FFR With Computational Fluid Dynamics: Results From CT-FFR CHINA Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 810625.	2.4	3
34	Hypertension and Brachydactyly Syndrome Associated With Vertebral Artery Malformation Caused by a <i>PDE3A</i> Missense Mutation. American Journal of Hypertension, 2020, 33, 190-197.	2.0	7
35	Long-term blood pressure outcomes of patients with adrenal venous sampling-proven unilateral primary aldosteronism. Journal of Human Hypertension, 2020, 34, 440-447.	2.2	6
36	Quantification of left atrial function in patients with non-obstructive hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking imaging: a feasibility and reproducibility study. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 1.	3.3	86

#	Article	IF	Citations
37	Impact of Lipoprotein(a) on Long-Term (Mean 6.2 Years) Outcomes in Patients With Three-Vessel Coronary Artery Disease. American Journal of Cardiology, 2020, 125, 528-533.	1.6	8
38	Surgical Treatment in Patients With Aortic Regurgitation Due to Takayasu Arteritis. Annals of Thoracic Surgery, 2020, 110, 165-171.	1.3	9
39	MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction. Radiology, 2020, 294, 275-286.	7.3	67
40	East Asian–Specific Common Variant in <i>TNNI3</i> Predisposes to Hypertrophic Cardiomyopathy. Circulation, 2020, 142, 2086-2089.	1.6	11
41	Clinical Scenario and Longâ€term Outcome of Childhood Takayasu Arteritis Undergoing 121 Endovascular Interventions: The Largest Cohort over a 15â€year Period. Arthritis Care and Research, 2020, 73, 1678-1688.	3.4	6
42	Premature Stroke Secondary to Severe Hypertension Results from Liddle Syndrome Caused by a Novel SCNN1B Mutation. Kidney and Blood Pressure Research, 2020, 45, 603-611.	2.0	7
43	Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia. Endocrine, 2020, 70, 607-615.	2.3	15
44	MRI Characteristics, Prevalence, and Outcomes of Hypertrophic Cardiomyopathy with Restrictive Phenotype. Radiology: Cardiothoracic Imaging, 2020, 2, e190158.	2.5	6
45	Platelet microRNA-15b protects against high platelet reactivity in patients undergoing percutaneous coronary intervention through Bcl-2-mediated platelet apoptosis. Annals of Translational Medicine, 2020, 8, 364-364.	1.7	6
46	Strengthening effects of bone marrow mononuclear cells with intensive atorvastatin in acute myocardial infarction. Open Heart, 2020, 7, e001139.	2.3	9
47	Value of a Machine Learning Approach for Predicting Clinical Outcomes in Young Patients With Hypertension. Hypertension, 2020, 75, 1271-1278.	2.7	35
48	Pediatric Liddle Syndrome Caused by a Novel <i>SCNN1G</i> Variant in a Chinese Family and Characterized by Early-Onset Hypertension. American Journal of Hypertension, 2020, 33, 670-675.	2.0	14
49	Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy. Heart Rhythm, 2020, 17, 1658-1663.	0.7	14
50	Precision cardiovascular medicine in China. Journal of Geriatric Cardiology, 2020, 17, 638-641.	0.2	1
51	Truncated Epithelial Sodium Channel $\hat{l}^2$ Subunit Responsible for Liddle Syndrome in a Chinese Family. Kidney and Blood Pressure Research, 2019, 44, 942-949.	2.0	4
52	Clinical Course, Management, and Outcomes of Pediatric Takayasu Arteritis Initially Presenting With Hypertension: A 16-year overview. American Journal of Hypertension, 2019, 32, 1021-1029.	2.0	9
53	Steroid metabolism gene variants and their genotype-phenotype correlations in Chinese early-onset hypertension patients. Hypertension Research, 2019, 42, 1536-1543.	2.7	2
54	Clinical course and prognostic factors of childhood Takayasu's arteritis: over 15-year comprehensive analysis of 101 patients. Arthritis Research and Therapy, 2019, 21, 31.	3.5	38

#	Article	IF	CITATIONS
55	Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease. European Heart Journal, 2019, 40, 3397-3405.	2.2	39
56	Prognostic Value of Plasma Big Endothelin-1 Level among Patients with Three-Vessel Disease: A Cohort Study. Journal of Atherosclerosis and Thrombosis, 2019, 26, 959-969.	2.0	9
57	Titinâ€truncating variants are associated with heart failure events in patients with left ventricular nonâ€compaction cardiomyopathy. Clinical Cardiology, 2019, 42, 530-535.	1.8	11
58	A Novel Frameshift Mutation of SCNN1G Causing Liddle Syndrome with Normokalemia. American Journal of Hypertension, 2019, 32, 752-758.	2.0	5
59	Predictive value of in-hospital white blood cell count in Chinese patients with triple-vessel coronary disease. European Journal of Preventive Cardiology, 2019, 26, 872-882.	1.8	31
60	The era of clinical application of gene diagnosis in cardiovascular diseases is coming. Chronic Diseases and Translational Medicine, 2019, 5, 214-220.	1.2	2
61	mTOR pathway in human cardiac hypertrophy caused by LEOPARD syndrome: a different role compared with animal models?. Orphanet Journal of Rare Diseases, 2019, 14, 252.	2.7	3
62	Novel Biomarkers for the Precisive Diagnosis and Activity Classification of Takayasu Arteritis. Circulation Genomic and Precision Medicine, 2019, 12, e002080.	3.6	13
63	Implications of Hyperuricemia in Severe Coronary Artery Disease. American Journal of Cardiology, 2019, 123, 558-564.	1.6	14
64	Tuberculosis in Takayasu arteritis: a retrospective study in 1105 Chinese patients. Journal of Geriatric Cardiology, 2019, 16, 648-655.	0.2	8
65	Anemia in patients with Takayasu arteritis: prevalence, clinical features, and treatment. Journal of Geriatric Cardiology, 2019, 16, 689-694.	0.2	2
66	Prognostic Values of Serum Chloride and Sodium Levels in Patients with Three-vessel Disease. Biomedical and Environmental Sciences, 2019, 32, 250-259.	0.2	2
67	A New Risk Factor Profile for Contrast-Induced Acute Kidney Injury in Patients Who Underwent an Emergency Percutaneous Coronary Intervention. Angiology, 2018, 69, 523-531.	1.8	12
68	The presentation and management of hypertension in a large cohort of Takayasu arteritis. Clinical Rheumatology, 2018, 37, 2781-2788.	2.2	22
69	Prevalence and risk factors associated with hypertension in the Chinese Qiang population. Clinical and Experimental Hypertension, 2018, 40, 427-433.	1.3	6
70	Validation of Predictive Value of Patterns of Nonadherence to Antiplatelet Regimen in Stented Patients Thrombotic Risk Score in Chinese Population Undergoing Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 2699-2704.	2.3	8
71	Evaluation of the Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Bleeding Score for Predicting the Long-term Out-of-hospital Bleeding Risk in Chinese Patients after Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 1406-1411.	2.3	4
72	Mutation profile of <i>FLNC</i> gene and its prognostic relevance in patients with hypertrophic cardiomyopathy. Molecular Genetics & Enomic Medicine, 2018, 6, 1104-1113.	1.2	34

#	Article	IF	CITATIONS
73	Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions. Chinese Medical Journal, 2018, 131, 262-267.	2.3	3
74	Cardiac Valve Involvement in Takayasu Arteritis Is Common: A Retrospective Study of 1,069 Patients Over 25 Years. American Journal of the Medical Sciences, 2018, 356, 357-364.	1,1	24
75	Liddle syndrome misdiagnosed as primary aldosteronism resulting from a novel frameshift mutation of SCNN1B. Endocrine Connections, 2018, 7, 1528-1534.	1.9	9
76	Prognostic Value of NT-proBNP in Stable Coronary Artery Disease in Chinese Patients after Percutaneous Coronary Intervention in the Drug-eluting Stent Era. Biomedical and Environmental Sciences, 2018, 31, 859-866.	0.2	5
77	Familial hypertrophic cardiomyopathy caused by a de novo Gly716Arg mutation of the $\hat{I}^2$ -myosin heavy chain. Cardiology in the Young, 2017, 27, 467-472.	0.8	4
78	Subclavian artery stenting for coronaryâ€subclavian steal syndrome. Catheterization and Cardiovascular Interventions, 2017, 89, 601-608.	1.7	7
79	Prognostic Significance of Plasma Highâ€Sensitivity Câ€Reactive Protein in Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2017, 6, .	3.7	31
80	Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in hypertension and associated with left ventricular remodeling. European Radiology, 2017, 27, 4620-4630.	4.5	26
81	Titin-Truncating Variants Increase the Risk of Cardiovascular Death in Patients With Hypertrophic Cardiomyopathy. Canadian Journal of Cardiology, 2017, 33, 1292-1297.	1.7	18
82	Plasma level of big endothelin-1 predicts the prognosis in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2017, 243, 283-289.	1.7	25
83	A Novel Method of Adrenal Venous Sampling via an Antecubital Approach. CardioVascular and Interventional Radiology, 2017, 40, 388-393.	2.0	12
84	Single Nucleotide Polymorphism rs10919543 in FCGR2A/FCGR3A Region Confers Susceptibility to Takayasu Arteritis in Chinese Population. Chinese Medical Journal, 2016, 129, 854-859.	2.3	6
85	Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. Chinese Medical Journal, 2016, 129, 2269-2274.	2.3	12
86	Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clinical and Experimental Hypertension, 2016, 38, 464-468.	1,3	64
87	The interval between carotid artery stenting and open heart surgery is related to perioperative complications. Catheterization and Cardiovascular Interventions, 2016, 87, 564-569.	1.7	2
88	Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention. Thrombosis Research, 2016, 141, 28-34.	1.7	26
89	Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis: Two-year results. International Journal of Cardiology, 2016, 205, 117-123.	1.7	35
90	Lack of association between polymorphisms in interleukin (IL)-12, IL-12R, IL-23, IL-23R genes and Takayasu arteritis in a Chinese population. Inflammation Research, 2016, 65, 543-550.	4.0	5

#	Article	IF	CITATIONS
91	Simultaneous Bilateral vs Unilateral Carotid Artery Stenting. Journal of Endovascular Therapy, 2016, 23, 258-266.	1.5	9
92	Predictors of Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. Circulation: Cardiovascular Interventions, 2016, 9, e002675.	3.9	21
93	Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention. Platelets, 2016, 27, 75-79.	2.3	17
94	Prevalence of Liddle Syndrome Among Young Hypertension Patients of Undetermined Cause in a Chinese Population. Journal of Clinical Hypertension, 2015, 17, 902-907.	2.0	46
95	Plasma Uric Acid as a Prognostic Marker in Patients WithÂHypertrophic Cardiomyopathy. Canadian Journal of Cardiology, 2015, 31, 1252-1258.	1.7	16
96	Female Sex Is Associated with Worse Prognosis in Patients with Hypertrophic Cardiomyopathy in China. PLoS ONE, 2014, 9, e102969.	2.5	48
97	Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. European Journal of Heart Failure, 2014, 16, 950-957.	7.1	53
98	Rare Variants in Genes Encoding MuRF1 and MuRF2 Are Modifiers of Hypertrophic Cardiomyopathy. International Journal of Molecular Sciences, 2014, 15, 9302-9313.	4.1	39
99	Clinical Manifestations and Longterm Outcome for Patients with Takayasu Arteritis in China. Journal of Rheumatology, 2014, 41, 2439-2446.	2.0	83
100	Percutaneous Transluminal Angioplasty for Symptomatic Pulmonary Stenosis in Takayasu Arteritis. Journal of Rheumatology, 2014, 41, 1856-1862.	2.0	22
101	Relationship Between ABCB1 Polymorphisms, Thromboelastography and Risk of Bleeding Events in Clopidogrel-Treated Patients With ST-Elevation Myocardial Infarction. Thrombosis Research, 2014, 134, 970-975.	1.7	25
102	MiRâ€451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting <scp>TSC</scp> 1. Journal of Cellular and Molecular Medicine, 2014, 18, 2266-2274.	3.6	112
103	One-year outcomes of percutaneous renal denervation for the treatment of resistant hypertension: the first Chinese experience. Chinese Medical Journal, 2014, 127, 1003-7.	2.3	1
104	Atorvastatin Enhance Efficacy of Mesenchymal Stem Cells Treatment for Swine Myocardial Infarction via Activation of Nitric Oxide Synthase. PLoS ONE, 2013, 8, e65702.	2.5	72
105	Mutations profile in Chinese patients with hypertrophic cardiomyopathy. Clinica Chimica Acta, 2005, 351, 209-216.	1.1	62